Search clinical trials for: Lantus (insulin glargine)

Total 3218 results

Sanofi

Completed

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (GetGoal-Duo1)

Type 2 Diabetes Mellitus

United States, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, South Africa, Swed... and more
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
University of Pittsburgh
Sanofi

Completed

Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings

Hyperglycemia | Type 2 Diabetes

United States
Dr. Muhammad Abdulghani

Unknown

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

Type 2 Diabetes

Qatar
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, France, Sweden, Poland, Turkey, Korea, Republic of, India, South Africa
Ain Shams University

Recruiting

Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis

Chronic Kidney Diseases

Egypt
Sanofi

Completed

Insulin Glargine in Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Sanofi

Completed

Extension to Study HMR1964A/3011 in Belgium

Diabetes Mellitus

Belgium
Northwestern University

Terminated

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Insulin Resistance, Diabetes | Hyperglycemia Steroid-induced

United States
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 1)

Diabetes Mellitus, Type 2

United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russian Federation, Slovakia, Spain, United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Spain, Denmark, Austria, Belgium, Serbia, Germany, Slovenia, Canada, France, Finland, Former Serbia and Montenegro, Czech Republic, Norway
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes (EFFICACY)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Argentina, Thailand, India, Korea, Republic of
Baylor College of Medicine

Completed

Lantus in the Treatment of Type 1 Diabetes Children

Type 1 Diabetes

United States
Biodel

Completed

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

Diabetes Mellitus

United States
Emory University

Completed

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery (SITACABG NonDM)

Coronary Artery Disease

United States
Emory University
Boston Medical Center; Rush University; University of Denver

Completed

Linagliptin Inpatient Trial

Type 2 Diabetes

United States
Novo Nordisk A/S

Recruiting

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Diabetes, Type 2

United States, India, Spain, Poland, South Africa, Bulgaria, Germany, Japan, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Italy, Mexico, Russian Federation, United Kingdom, Spain, Malaysia, Croatia, Greece, Korea, Republic of, Japan, South Africa, Algeria, Thailand, Argentina, Brazil, Canada, Romania
Novo Nordisk A/S

Completed

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of, Japan, Malaysia, Taiwan, Thailand, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Puerto Rico, Slovakia, Canada, South Africa, United Kingdom, Czech Republic
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™) (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

Austria
Emory University
American Diabetes Association

Completed

ADA Linagliptin in Long Term Care

Diabetes

United States
Emory University

Completed

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Hyperglycemia

United States
Sanofi
Population Health Research Institute

Completed

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN)

Diabetes Mellitus, Non-Insulin-Dependent

United States, France, Brazil, Poland, Romania, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, India, Philippines, Russian Federation, Slovakia, Mexico, Argentina, Croatia, Austria, Denmark, Finland, Hungary, Lithuania, Norw... and more
Eli Lilly and Company

Completed

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus (IMAGINE 5)

Diabetes Mellitus, Type 2

United States, Germany, Israel, Czechia, Spain, Russian Federation, Romania, Puerto Rico, Greece
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Diabetes Mellitus, Type 2

United States, Italy, Canada, Germany, Czechia
Novo Nordisk A/S

Completed

Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Germany, United Kingdom, Austria, Belgium, France, Ireland
Sanofi

Completed

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Diabetes Mellitus

United States
Baylor College of Medicine

Completed

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

Type 1 Diabetes

United States
Sanofi

Completed

ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2

Italy
HaEmek Medical Center, Israel

Completed

Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards

Diabetes Mellitus Type 2
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus (EDITION JUNIOR)

Type 1 Diabetes Mellitus

France, Czechia, Chile, Israel, Spain, Hungary, Mexico, Serbia, Japan, Canada, Brazil, Sweden, Denmark, Argentina, United States, Bulgaria, Germany, Italy, Latvia, North Macedonia, Poland, Romania, Russian Federation, United Kingdom
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) (ONWARDS 4)

Diabetes Mellitus, Type 2

United States, Japan, Mexico, Russian Federation, Netherlands, Belgium, Italy, India, Romania
Novo Nordisk A/S

Completed

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, France, United Kingdom, Russian Federation, Germany, South Africa
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, United Kingdom, Belgium, Norway, Germany, Greece
Novo Nordisk A/S

Completed

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Spain, Russian Federation, Turkey, Austria, India, Korea, Republic of

Search clinical trials for: Lantus (insulin glargine)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations